HbA1c fell by 2.01 to 2.30 points on tirzepatide against 1.86 on semaglutide, and weight fell by 7.6 to 11.2 kg against 5.7 kg. It was published in the New England Journal of Medicine in 2021.1,2
How the trial was run
The trial was open-label, so participants knew which drug they took, and it lasted 40 weeks. People were assigned in equal shares to the four groups. At the start their average HbA1c was 8.28%, their average age 56.6 years and their average weight 93.7 kg.1 The main outcome was the change in HbA1c from the start to week 40; weight was a secondary outcome, reported as the change in kilograms.
The semaglutide dose matters for reading the result. The trial used 1 mg. The Ozempic label now goes up to 2 mg, and Wegovy, for weight, to 2.4 mg and 7.2 mg, so SURPASS-2 compared tirzepatide with a lower semaglutide dose than is now available.3,4
What it found
- HbA1c fell by 2.01, 2.24 and 2.30 points on tirzepatide 5, 10 and 15 mg, against 1.86 on semaglutide. Every tirzepatide dose was better.
- Weight fell by 1.9, 3.6 and 5.5 kg more on the three tirzepatide doses than on semaglutide. On the Mounjaro label that is 7.6, 9.3 and 11.2 kg, against 5.7 kg.
- On the Mounjaro label, from a start of 8.3%, an HbA1c under 7% was reached by 82% on 5 mg and 86% on 10 and 15 mg, against 79% on semaglutide.
The Mounjaro label adds two details. Fasting blood sugar fell by 55, 59 and 60 mg/dL on the three tirzepatide doses, against 49 on semaglutide. And extra diabetes medicine had to be started in only 1% to 3% of people in any group, so the comparison was not blurred by rescue treatment.2
Frías et al., 2021; MOUNJARO label, Table 5.1,2
Side effects
Side effects were similar in kind on both drugs and mostly mild to moderate. Nausea was reported by 17% to 22% on tirzepatide and 18% on semaglutide, diarrhea by 13% to 16% and 12%, and vomiting by 6% to 10% and 8%. Low blood sugar under 54 mg/dL was uncommon on tirzepatide, at 0.2% to 1.7% across doses.1 Our page on Mounjaro side effects sets out when they start.
What it means
The difference in blood sugar was modest: 0.15 to 0.45 points of HbA1c. The difference in weight was larger and grew with the dose. A later trial in people without diabetes, SURMOUNT-5, compared the drugs at their weight-management doses and found 20.2% against 13.7%.5 Our page on Ozempic and Mounjaro sets both labels side by side.
Why open-label matters
In an open-label trial, participants and their doctors know which drug is being taken. That can shape how side effects are reported and how closely diet and other medicines are managed. For HbA1c and weight, which are measured objectively, the risk of bias is smaller than for symptoms, but it is one reason a blinded comparison would carry more weight. SURMOUNT-5, the later comparison, was open-label too.1,5
Limits
The trial was open-label and funded by Eli Lilly, the maker of tirzepatide. It used semaglutide 1 mg rather than the higher doses available today, and it lasted 40 weeks.1 Those three facts are the usual caveats when its result is quoted.
Sources
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503-515. Funded by Eli Lilly; NCT03987919. doi:10.1056/NEJMoa2107519
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; section 14.3. accessdata.fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 2. accessdata.fda.gov
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 2. accessdata.fda.gov
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
Related analyses
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Ozempic vs Zepbound: two drugs, two labels, and the trials that compared them
Mounjaro dosing schedule: 2.5 mg to 15 mg, week by week, with your own dates
Mounjaro side effects: how common each one is by dose, and when they ease
Log your doses, weight and HbA1c and see them together.
Open Dose Insider